71 / 80
69
45.- RAJANI SHAKYA, B SUBBA RAO, BHAWANA
SHRESTHA. Incidence of Hepatotoxicity Due to An-
titubercular Medicines and Assessment of Risk Factors
Annals of Pharmacotherapy s 2004; 38: 1074-9.
46.- MEHTA S. Malnutrition and drugs: clinical implica-
tions. Dev Pharmacol Ther 1990; 15: 159-65.
47.- WONG WM, WU PC, YUEN MF, CHENG CC, YEW
WW, WONG PC, et al. Antituberculosis drug-related
liver dysfunction in chronic hepatitis B infection. He-
patology 2000; 31: 201-6.
48.- HOFFMANN CJ, CHARALAMBOUS S, THIO CL,
MARTIN DJ, PEMBA L, FIELDING KL, et al. Hepa-
totoxicity in an African antiretroviral therapy cohort: the
effect of tuberculosis and hepatitis B. AIDS 2007; 21:
1301-8.
49.- UNGO JR, JONES D, ASHKIN D, HOLLENDER ES,
BERNSTEIN D, ALBANESE AP, et al. Antitubercu-
losis drug-induced hepatotoxicity. The role of hepatitis
C virus and the human immunodeficiency virus. Am J
Respir Crit Care Med 1998; 157: 1871-6.
50.- JAIN MK. Drug-induced liver injury associated with
HIV medications. Clin Liver Dis. 2007; 11: 615-9.
51.- NÚÑEZ M. Hepatotoxicity of antiretrovirals: inciden-
ce, mechanisms and management. J Hepatol 2006; 44:
S132-S139.
52.- YILDIZ A, SEVER MS, TURKMEN A. Tuberculosis
after renal transplantation: experience of one Turkish
centre. Nephrol Dial Transplant 1998; 13: 1872-5.
53.- ANTONY SJ, YNARES C, DUMMER JS. Isoniazid
hepatotoxicity in renal transplant recipients. Clin Trans-
plant 1997; 11: 34-7.
54.- WRIGHT JM, STOKES EF, SWEENEY VP. Isoniazid-
induced carbamazepine toxicity and vice versa: a double
drug interaction. N Engl J Med 1982; 307: 1325-7.
55.- D VALIQUETTE C, PELLETIER M, PARISIEN I, RO-
CHER I, MENZIES D. Incidence of serious side effects
from first-line antituberculosis drugs among patients
treated for active tuberculosis. Am J Respir Crit Care
Med 2003; 167: 1472-7.
56.- GROSSET J, TRUFFOT-PERNOT C, LACROIX C, JI
B. Antagonism between isoniazid and the combination
pyrazinamide-rifampin against tuberculosis infection
in mice. Antimicrob Agents Chemother. 1992; 36:
548-51.
57.- JASMER RM, SAUKKONEN JJ, BLUMBERG HM,
DALEY CL, BERNARDO J, VITTINGHOFF E, et al.
Short-course rifampin and pyrazinamide compared with
isoniazid for latent tuberculosis infection: a multicenter
clinical trial. Ann Intern Med 2002; 137: 640-7.
58.- AMERICAN THORACIC SOCIETY, CENTERS FOR
DISEASE CONTROL, INFECTIOUS DISEASES
SOCIETY OF AMERICA. Treatment of tuberculosis.
Am J Respir Crit Care Med 2003; 167: 603-62.
59.- JOINT TUBERCULOSIS COMMITTEE OF THE
BRITISH THORACIC SOCIETY. Chemotherapy and
management of tuberculosis in the United Kingdom:
recommendations 1998. Thorax 1998; 53: 536-48.
60.- MCNEILL L, ALLEN M, ESTRADA C, COOK
P. Pyrazinamide and rifampin vs isoniazid for the
treatment of latent tuberculosis: improved completion
rates but more hepatotoxicity. Chest 2003; 123: 102-6.
61.- SINGANAYAGAM A, SRIDHAR S, DHARIWAL J,
ABDEL-AZIZ D, MUNRO K, CONNELL DW, et al.
A comparison between two strategies for monitoring
hepatic function during anti-tuberculous therapy. Am J
Respir Crit Care Med 2012; 185: 653-9.
62.- WATKINS PB. Biomarkers for the diagnosis and ma-
nagement of drug-induced liver injury. Semin Liver Dis
2009; 29: 393-9.
63.- SCHARER L, SMITH JP. Serum transaminase eleva-
tions and other hepatic abnormalities in patients recei-
ving isoniazid. Ann Intern Med 1969; 71: 1113-20.
64.- SENIOR JR. Monitoring for hepatotoxicity: what is the
predictive value of liver ‘‘function’’ tests? Clin Pharma-
col Ther 2009; 85: 331-4.
65.- SHARMA SK, SINGLA R, SARDA P, MOHAN A,
MAKHARIA G, JAYASWAL A, et al. Safety of 3 di-
fferent reintroduction regimens of antituberculosis drugs
after development of antituberculosis treatment-induced
hepatotoxicity. Clin Infect Dis 2010; 50: 833-9.
Correspondencia a:
Dr. Fernando Tirapegui S.
Departamento de Enfermedades Respiratorias,
Pontificia Universidad Católica de Chile.
Diagonal Paraguay 362, piso 6, Santiago, Chile.
Email:
ftirapegui@uc.clHepatotoxicidad por fármacos anti-tuberculosis
Rev Chil Enferm Respir 2018; 34: 62-69